eif-3.I Antibody

What is eIF3 and what roles does it play in cellular processes?

eIF3 is a multi-subunit protein complex that plays a crucial role in translation initiation, acting as a coordinator of the cellular machinery that positions ribosomes at the mRNA start codon. Recent research has revealed that beyond its canonical role in general translation, eIF3 has specialized functions:

• It interacts with specific 3'-UTR regions of highly translated mRNAs, particularly near the poly(A) tail

• It plays a critical role in translational regulation during stem cell differentiation

• It has been identified as a novel autoantigen in certain autoimmune conditions (0.44% of polymyositis patients)

• It participates in T cell activation by regulating translation of T cell receptor (TCR) subunits

Which eIF3 subunits are most commonly studied with antibodies?

Several eIF3 subunits are frequently targeted in research applications:

The PAR-CLIP studies performed with the eIF3 complex identified eIF3 subunits EIF3A, EIF3B, EIF3D, and to a lesser extent, EIF3G as the four subunits presenting significant amounts of RNA crosslinks .

What are the optimal conditions for using eIF3A antibodies in various applications?

Based on validated antibody data, the following conditions are recommended:

How can I design experiments to study eIF3-RNA interactions?

The Quick-irCLIP methodology has been successfully used to identify RNA transcripts that interact with eIF3:

• UV crosslinking of cells (0.15 J/cm² of 254 nm UV light)

• Cell lysis followed by RNase I treatment to fragment RNAs

• Immunoprecipitation using anti-eIF3 subunit antibodies (typically anti-EIF3B)

• Dephosphorylation of protein-bound transcripts

• IR adaptor ligation

• RNA-protein complex visualization via SDS-PAGE

• RNA extraction and sequencing analysis

When studying eIF3-RNA interactions, researchers should consider:

• The transient nature of some interactions may require protein-protein crosslinkers like DSP (dithiobis(succinimidyl propionate))

• Different cell types show varying patterns of eIF3-RNA interactions (e.g., neural progenitors vs. T cells)

• Controls should include immunoprecipitation with non-specific IgG and RNA-seq of input samples

How can eIF3 antibodies be used to study translational control in T cell activation?

Recent research has demonstrated that eIF3 plays a critical role in T cell activation through translation regulation:

• eIF3 interacts with select immune system-related mRNAs including TCR subunits TCRA and TCRB

• This interaction occurs at the 3'-UTRs of these mRNAs

• The binding depends on CD28 coreceptor signaling

• This mechanism regulates a burst in TCR translation required for robust T cell activation

Experimental approach:

• Use anti-eIF3 antibodies to immunoprecipitate complexes from resting and activated T cells

• Perform RNA-seq on the bound transcripts to identify differentially enriched mRNAs

• Validate specific interactions using reporter constructs with identified 3'-UTRs

• Assess functional consequences through targeted knockdown of eIF3 subunits

What role does eIF3 play in stem cell differentiation and how can antibodies help study this process?

eIF3 is involved in translational regulation during stem cell differentiation:

• During early differentiation of human pluripotent stem cell-derived neural progenitor cells, a global increase in protein synthesis occurs

• eIF3 predominantly crosslinks with 3'-UTR termini of multiple mRNA isoforms, adjacent to the poly(A) tail

• This engagement at 3'-UTR ends depends on polyadenylation

• High eIF3 crosslinking correlates with high translational activity, as determined by ribosome profiling

Experimental strategies:

• Compare eIF3-RNA interactions between undifferentiated and differentiated cells using Quick-irCLIP

• Correlate binding patterns with translation efficiency using ribosome profiling

• Examine alternative polyadenylation using APA-Seq

• Test the functional significance by mutating identified binding sites

How can I troubleshoot specificity issues with eIF3 antibodies?

When working with eIF3 antibodies, ensuring specificity is critical:

For definitive validation:

• Perform mass spectrometry on immunoprecipitated proteins

• Use multiple antibodies targeting different epitopes of the same protein

• Include genetic validation through siRNA knockdown or CRISPR knockout

What challenges exist in detecting eIF3-protein interactions and how can they be addressed?

The search results highlight several challenges in studying eIF3-protein interactions:

• Transient interactions: "eIF3 interactions with poly(A)-binding proteins are transient and eIF3 immunoprecipitation results in the disruption of these complexes"

  Solution: Use protein-protein crosslinkers like DSP before cell collection and immunoprecipitation

• Complex integrity: eIF3 is a 13-subunit complex; interactions might involve multiple subunits

  Solution: Immunoprecipitate with antibodies against different subunits to verify consistent interactions

• RNA-dependent interactions: Some protein-protein interactions may be mediated by RNA

  Solution: Include RNase treatment controls to distinguish direct protein interactions from RNA-mediated ones

How can eIF3 antibodies be used in autoimmune disease research?

eIF3 has been identified as a novel autoantigen in idiopathic inflammatory myositis:

• Autoantibodies against eIF3 were detected in 0.44% of polymyositis (PM) patients

• These autoantibodies were not found in other autoimmune conditions or healthy controls

• Indirect immunofluorescence demonstrated a fine cytoplasmic speckled pattern

• Anti-eIF3-positive patients showed no history of malignancy or interstitial lung disease and had a favorable response to treatment

Research methodology:

• Screen patient sera using radio-labelled protein immunoprecipitation

• Confirm with indirect immunofluorescence

• Identify the specific autoantigen using mass spectrometry

• Validate findings with commercial anti-eIF3 antibodies and IPP-Western blotting

What potential exists for using eIF3 knowledge in therapeutic development?

Recent findings suggest therapeutic applications based on eIF3 research:

• CAR-T cell engineering: "Use of the TCRA or TCRB 3'-UTRs to control expression of an anti-CD19 chimeric antigen receptor (CAR) improves the ability of CAR-T cells to kill tumor cells in vitro"

• Diagnostic biomarkers: Anti-eIF3 autoantibodies may serve as biomarkers in a subset of polymyositis patients

• Targeted translation regulation: Understanding eIF3-mediated translation control mechanisms could lead to therapeutic approaches for conditions involving dysregulated protein synthesis

Experimental validation of these applications requires:

• Functional testing of engineered constructs in relevant cell types

• Larger cohort studies for biomarker validation

• Mechanistic studies to identify potential intervention points